Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Tetrahydromagnolol: A GPCR Assay Design Framework
2026-09-21
Tetrahydromagnolol is a peripheral CB2 receptor agonist with a distinctive CB2–GPR55 pharmacology. This guide translates its reported potency values and a new GPCR–cytoskeleton metastasis study into a mechanism-resolved experimental strategy.
-
Etomoxir: CPT-1 Inhibition in Metabolic Research
2026-09-21
Etomoxir is a cell-permeable, irreversible CPT-1 inhibitor used to test fatty acid oxidation dependence in cellular and immunometabolic systems. R-(+)-Etomoxir research requires attention to stereochemical identity, concentration-dependent DGAT inhibition, and the limits of translating EAE findings to human disease.
-
SW033291: A Translational Map for Regeneration
2026-09-20
SW033291 is a potent 15-PGDH inhibitor that links prostaglandin E2 elevation with hematopoiesis stimulation and tissue regeneration research. This thought-leadership guide translates biochemical potency, marrow-cell assays, and emerging muscle-repair evidence into a disciplined strategy for target validation and translational study design.
-
SB 431542: A Practical ALK5 Inhibitor Workflow
2026-09-19
SB 431542 enables focused interrogation of ALK5-dependent TGF-β signaling, from Smad2 phosphorylation assays to intestinal epithelial and glioma models. This guide translates reference-study findings into executable workflows, controls, and troubleshooting strategies without treating pathway inhibition as proof of therapeutic benefit.
-
Pollen Interference in EEM Hazard Classification
2026-09-18
A 2024 Molecules study shows that pollen can distort excitation–emission matrix fluorescence classification of hazardous bioaerosol components. Combining spectral preprocessing, fast Fourier transform features, and random-forest modeling improved discrimination across 31 sample types and offers a practical strategy for reducing pollen-associated misclassification.
-
X-Gal Workflow for Blue-White Screening
2026-09-18
Build a more reliable blue-white colony screening workflow with practical guidance on substrate preparation, plate conditions, clone selection, and confirmation. The article also shows how X-Gal can support plasmid construction for olfactory receptor and iRhom2 studies without being mistaken for a direct pathway assay.
-
Zolmitriptan Workflows for 5-HT1B Research
2026-09-17
Build reproducible receptor-signaling, vascular, and neuropeptide-release assays with Zolmitriptan, a selective 5-HT1B receptor agonist for migraine and cluster headache research. This workflow emphasizes solvent control, subtype-resolved experiments, orthogonal validation, and time-resolved assay design without overstating evidence from unrelated lysosomal studies.
-
LINC01977, Super-Enhancers, and SMAD3 in Early LUAD
2026-09-17
Zhang et al. identify LINC01977 as a super-enhancer-hijacked long noncoding RNA that reinforces canonical TGF-β/SMAD3 signaling in early-stage lung adenocarcinoma. The study connects tumor-associated macrophage activity, enhancer regulation, SMAD3 nuclear function, and ZEB1-mediated malignancy, providing a mechanistic framework for studying epigenetic drivers of relapse and invasion.
-
Sex-Biased Gene Expression in Neural hESCs
2026-09-16
Pottmeier and colleagues used multiple male- and female-derived human embryonic stem cell lines to identify genetic sex biases during neural differentiation without treating hormonal exposure as the primary driver. Their transcriptomic analysis highlights neurodevelopmental candidate genes, Y-linked regulators, and a stronger contribution from the male transcriptome, providing a framework for studying sex-dependent developmental trajectories.
-
Bay 11-7821 in NF-κB Inflammation Workflows
2026-09-16
Bay 11-7821 (BAY 11-7082) gives researchers a practical way to test whether IKK–NF-κB activity links innate immune stimulation to cytokine output, cell survival, or tumor-cell growth. This workflow-focused guide covers monocyte inflammation assays, cancer models, controls, dosing logic, and troubleshooting.
-
25-Hydroxycholesterol Reprograms Tumor Macrophages
2026-09-15
The 2024 Immunity study identifies CH25H-derived 25-hydroxycholesterol as an immunometabolic checkpoint that links lysosomal sterol handling to AMPKα–STAT6 signaling and ARG1 production in tumor-associated macrophages. Its findings provide a mechanistic explanation for macrophage-mediated immune suppression and show why CH25H targeting can improve T-cell surveillance and anti-PD-1 responses.
-
Autophagy and Cementoblast Mineralization Under Compression
2026-09-15
The reference study identifies autophagy as a functional mediator of cementoblast mineralization under compressive force and links this response to a periostin/β-catenin signaling axis. Its cell, transcriptomic, and mouse experiments provide a mechanistic framework for understanding cementum damage during orthodontic tooth movement and for designing pathway-focused regeneration studies.
-
Sulfo-NHS-LC-Biotin: Practical Labeling Guide
2026-09-14
Sulfo-NHS-LC-Biotin provides covalent biotin labeling of primary amines on proteins, peptides, and accessible cell-surface proteins in aqueous workflows. It is suited to permanent extracellular tagging and subsequent biotin-avidin capture, but not to reversible labeling or intracellular targets.
-
Protease Inhibitor Cocktail for OXPHOS Assays
2026-09-14
Discover how a Protease Inhibitor Cocktail and EDTA-Free Protease Inhibitor improve protein preservation and interpretation in dual-genome OXPHOS experiments. This guide connects protease control with LRPPRC–dasatinib assay design, sample integrity, and practical workflow decisions.
-
SMAD3 Inhibition and ADAMTS-5 in Early Osteoarthritis
2026-09-13
Xiang et al. show that pharmacologic SMAD3 inhibition lowers ADAMTS-5 while increasing miRNA-140 in inflammatory chondrocytes and early osteoarthritis cartilage. The study links the TGF-β signaling pathway to a potentially actionable miRNA-mediated mechanism of cartilage protection, while also defining important limits for translation beyond the rat model.